Home > Insider Trading > Filing (0001209191-18-027114)

Filing Details

Accession Number:: 0001209191-18-027114
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-05-01 16:37:26
Reporting Period:: 2018-04-30

Accepted Time:: 2018-05-01 16:37:26
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1035354	Eloxx Pharmaceuticals Inc.	ELOX	Services-Commercial Physical & Biological Research (8731)	841368850

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1726029	L.p. Iv (Cayman) Pontifax	C/O Eloxx Pharmaceuticals, Inc. 950 Winter Street, 4Th Floor North Waltham MA 02451	No	No	Yes	No
1726030	L.p. Iv (China) Pontifax	C/O Eloxx Pharmaceuticals, Inc. 950 Winter Street, 4Th Floor North Waltham MA 02451	No	No	Yes	No
1726039	Pontifax (Israel) Iv, L.p.	C/O Eloxx Pharmaceuticals, Inc. 950 Winter Street, 4Th Floor North Waltham MA 02451	No	No	Yes	No
1726334	Ltd. (2015) G.p. 4 Management Pontifax	C/O Eloxx Pharmaceuticals, Inc. 950 Winter Street, 4Th Floor North Waltham MA 02451	No	No	Yes	No
1726353	L.p. Gp Iv Pontifax	C/O Eloxx Pharmaceuticals, Inc. 950 Winter Street, 4Th Floor North Waltham MA 02451	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-04-30	84,041	$9.75	468,585	No	4	P	Indirect	By Pontifax Investment Fund
Common Stock	Acquisiton	2018-04-30	172,626	$9.75	962,504	No	4	P	Indirect	By Pontifax Investment Fund
Common Stock	Acquisiton	2018-04-30	93,333	$9.75	520,396	No	4	P	Indirect	By Pontifax Investment Fund

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Pontifax Investment Fund
No	4	P	Indirect	By Pontifax Investment Fund
No	4	P	Indirect	By Pontifax Investment Fund

Footnotes

Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018.
Represents shares of the Issuer held by Pontifax (Cayman) IV L.P. ("Cayman IV"). Pontifax IV GP L.P. ("Pontifax IV") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Management 4, Pontifax IV and Cayman IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Management 4, Pontifax IV and Israel IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
Represents shares of the Issuer held by Pontifax (China) IV L.P. ("China IV"). Pontifax IV GP L.P. is the general partner of China IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Management 4, Pontifax IV and China IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.